Pacira BioSciences Under Governance Pressure as DOMA Calls for Change and Board Restructuring

Pacira BioSciences Faces Corporate Governance Challenge Amid Calls for Change

Pacira BioSciences, a biopharmaceutical company specializing in non-opioid pain management solutions, is currently under scrutiny from its shareholder DOMA Perpetual Capital Management LLC. This investment firm, which holds approximately 6.83% of Pacira's shares, has publicly urged the company's board to implement significant changes. DOMA’s call to action includes initiating a formal sales process and evaluating current executive compensation and spending practices, which they describe as excessive and unjustified. The firm’s stance signals a growing concern over corporate governance within Pacira, raising critical questions about the board's effectiveness in overseeing executive decisions and operational expenditures.

In a statement released on December 30, 2025, DOMA outlines its intention to nominate three independent director candidates for Pacira's upcoming 2026 annual stockholders' meeting. The firm emphasizes the necessity for enhanced fiduciary oversight and accountability from the board, suggesting that the current governance structure may not adequately serve the interests of shareholders. By nominating independent directors, DOMA aims to introduce fresh perspectives and better align executive actions with shareholder expectations, particularly in the context of rising operational costs and executive pay.

DOMA’s actions reflect broader trends in the investment landscape, where shareholders increasingly demand transparency and responsible management from corporate boards. As Pacira BioSciences navigates these challenges, it must address the concerns raised by DOMA to maintain investor confidence and ensure sustainable growth. The firm plans to file a preliminary proxy statement and a white proxy card with the Securities and Exchange Commission (SEC) related to its director nominations, encouraging all stockholders to review the forthcoming proxy materials, which will be available for free on the SEC's website.

As these developments unfold, stakeholders will closely monitor how Pacira BioSciences responds to the mounting pressure from DOMA and other investors. The outcome of this shareholder activism may influence not only the company's governance practices but also its long-term strategic direction in the competitive biopharmaceutical industry.